Ia in early molecular diagnostic tests and in tailor-made therapy, the 9th at Gemelli

On Monday, at the Fondazione Policlinico Università Agostino Gemelli Irccs in Rome, in room 810 (eighth floor), the ECM Course 'Impact: Integrating Molecular Biology, Precision Therapy and AI: Shaping the Future of Lung Cancer Treatment' will be held, with the aim of exploring current knowledge in the molecular biology of lung cancer (tissue biopsy and liquid biopsy) and evaluating in a multidisciplinary manner the implications that such biological information has or will have in the future in the diagnostic and curative pathway of patients affected by lung cancer.

"The management of lung cancer is becoming increasingly complex - says Filippo Lococo, associate professor of Thoracic Surgery at the Faculty of Medicine and Surgery of the Catholic University of Rome and medical director of the Thoracic Surgery Unit of the Fondazione Policlinico Universitario Agostino Gemelli Irccs - with the increase in detailed knowledge of molecular biology data and with the evolution of emerging therapies associated with them. The analysis of the biomolecular pattern in tumor tissue has already partly revolutionized clinical practice in advanced stages and, thanks to this and to the knowledge of the tumor microenvironment, new integrated treatments have been developed in recent years in locally advanced stages and more recently also in the earliest stages".

The Ecm Impact course - a note reports - aims to promote a better understanding of the potential of AI, which will lead to a more frequent use of early molecular diagnostic tests and personalized treatments based on the biological characteristics of each individual tumor. The integration of different skills and the discussion between the numerous actors involved in the multidisciplinary management of Nsclc will clarify the best strategies to preserve and optimize the management of biological material, highlighting any critical issues and solutions. This will allow participants to understand the centrality of pathological and biological data in the multidisciplinary management of Nsclc and to actively contribute to the implementation of strategies useful for improving the management of the material and biological data.

The event will be organized in 3 sessions: 1. Integrating Molecular Biology and AI in screening and early stage lung cancer; 2. Biologically based therapeutic strategies in locally advanced NSCLC; 3. Biologically based therapeutic strategies in unresectable and advanced NSCLC.